The introduction of the COVID-19 prevention drug Evusheld in Korea has been confirmed. The KDCA supplementary budget of 4.9083 trillion won was confirmed yesterday (29th), which includes securing a shortage of living support, paid vacation expenses, quarantine hospitalization, and home treatment expenses due to a surge in confirmed cases. The government has decided to spend 39.6 billion won of the budget to introduce a new 20,000 doses of Evusheld by AstraZeneca, an antibody treatment for the purpose of preventing COVID-19 infection and severe immunity.

As a result, Evusheld, the first antibody complex for preventing the COVID-19 in Korea, is expected to be prescribed to immunodeficiency patients.